FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to spiro-5,6-dihydro-4H-2,3,5,10b-tetra-aza-benzo[e]azulene derivatives of formula I, where X-Y represents C(RaRb)-O, where each of Ra and Rb independently represents H or C1-4-alkyl, C(RcRd)-S(O)p, where each of Rc and Rd independently represents H, C(O)O, CH2OCH2, CH2CH2O, Z represents CH or N； R1 represents halogeno, R2 represents H, C1-6-alkyl, non-substituted or having as substituents one OH, -(CH2)q-Re, where Re represents pyridyl, -C(O)-C1-6-alkyl, -C(O)(CH2)qNRiRii, -C(O)O-C1-6-alkyl, -S(O)2NRiRii, each of Ri and Rii independently represents C1-6-alkyl, R3 represents Cl or F, n has value 1 or 2, m has value 0, 1, p has value 0 or 2, q has value 1, or to their pharmaceutically acceptable salts. Invention also relates to pharmaceutical composition, possessing antagonistic activity with respect to receptors V1a, on the basis of said compounds.EFFECT: obtained are novel compounds and pharmaceutical composition on their basis, which can be applied in medicine as drugs of peripheral and central action in case of the following states: dysmenorrhea, male or female sexual disfunction, hypertension, chronic heart failure, inadequate secretion of vasopressin, liver cirrhosis, nephritic syndrome, anxiety, depressive disorders, obsessive-compulsive disorder, autism spectrum disorders, schizophrenia and aggressive behaviour.20 cl, 10 tbl, 37 exИзобретение относится к спиро-5,6-дигидро-4H-2,3,5,10b-тетрааза-бензо[е]азуленовым производным Формулы Iгде X-Y представляет собой C(RaRb)-O, где каждый из Ra и Rb независимо представляет собой Н или C1-4-алкил, C(RcRd)-S(O)p, где каждый из Rc и Rd независимо представляет собой Н, С(O)O, СН2ОСН2, СН2СН2О, Z представляет собой CH или N； R1 представляет собой галогено, R2 представляет собой Н, C1-6-алкил, незамещенный или имеющий в качестве заместителей один ОН, -(CH2)q-Re, где Re представляет собой пиридил, -С(O)-С1-6-алкил, -C(O)(CH2)qNRiRii, -С(O)O-С1-6-алкил, -S(O)2NRi
